Predictors of selecting atomoxetine therapy for children with attention-deficit-hyperactivity disorder

Pharmacotherapy

Volumn 25, Issue 11 I, 2005, Pages 1541-1549

  Van Brunt, David L ^a   Johnston, Joseph A ^a   Ye, Wenyu ^a   Pohl, Gerhardt M ^a   Sun, Pei J ^a   Sterling, Kimberly L ^a   Davis, Martha E ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

ADHD; Administrative claims; Atomoxetine; Attention deficit hyperactivity disorder; Managed care; Stimulants; Treatment selection

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ANXIOLYTIC AGENT; ATOMOXETINE; DEXMETHYLPHENIDATE; LONG ACTING DRUG; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; NEUROLEPTIC AGENT; PEMOLINE; SEROTONIN UPTAKE INHIBITOR; SHORT ACTING DRUG; TRANQUILIZER; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; COHORT ANALYSIS; CONTROLLED DRUG RELEASE; DELAYED DRUG RELEASE; DRUG CHOICE; DRUG SELECTIVITY; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; PREDICTION; PRESCRIPTION; SUSTAINED DRUG RELEASE;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHILD BEHAVIOR; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MANAGED CARE PROGRAMS; PROPYLAMINES; RETROSPECTIVE STUDIES;

EID: 27644593448     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.11.1541     Document Type: Article

References (17)

1. Jadad AR, Boyle M, Cunningham C, Kim M, Schachar R. Treatment of attention-deficit/hyperactivity disorder. Rockville, MD: Agency for Healthcare Research and Quality, 1999.
2. Kavale K. The efficacy of stimulant drug treatment for hyperactivity: a meta-analysis. J Learn Disabil 1982;15:280-9.
3. Castellanos FX, Giedd JN, Elia J, et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry 1997;36:589-96.
4. Ahmann PA, Waltonen SJ, Olson KA, Theye FW, Van Erem AJ, LaPlant RJ. Placebo-controlled evaluation of Ritalin side effects. Pediatrics 1993;91:1101-6.
5. Barkley RA, McMurray MB, Edelbrock CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics 1990;86:184-92.
6. Fitzpatrick PA, Klorman R, Brumaghim JT, Borgstedt AD. Effects of sustained-release and standard preparations of methylphenidate on attention deficit disorder. J Am Acad Child Adolesc Psychiatry 1992;31:226-34.
7. MTA Cooperative Group. National Institute of Mental Health multimodal treatment study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 2004;113:762-9.
8. Pelham WE Jr, Greenslade KE, Vodde-Hamilton M, et al. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 1990;86:226-37.
9. McCabe SE, Teter CJ, Boyd CJ. The use, misuse and diversion of prescription stimulants among middle and high school students. Subst Use Misuse 2004;39:1095-116.
10. Stockl KM, Hughes TE, Jarrar MA, Secnik K, Perwien AR. Physician perceptions of the use of medications for attention deficit hyperactivity disorder. J Manag Care Pharm 2003;9:416-23.
11. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002;159:1896-901.
12. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study [online exclusive article]. Pediatrics 2001;108:E83. Available from http://pediatrics. aappublications.org/ cgi/content/full/108/5/e83.
13. Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 2002;63(suppl 12):50-5.
14. Pliszka SR. Non-stimulant treatment of attention-deficit/ hyperactivity disorder. CNS Spectr 2003;8:253-8.
15. American Academy of Pediatrics, Subcommitte on Attention-Deficit/ Hyperactivity Disorder. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. American Academy of Pediatrics. Pediatrics 2001;108:1033-44.
16. Degrandpre R. Ritalin nation: rapid-fire culture and the transformation of human consciousness. New York: W.W. Norton & Company; 2000.
17. Office of Applied Studies. Results from the 2003 national survey on drug use and health: detailed tables. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004.